Business
Medincell to Participate in Leerink and Jefferies Miami Investor Conferences, March 8 – 11, 2026
MONTPELLIER, France, March 04, 2026--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced its participation to the 2026 Leerink Global Healthcare Conference and Jefferies Biotech on the Beach Summit in Miami, Florida, March 8 – 11, 2026.
About this update from Medincell Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1772,"height":295,"url":"https://media.zenfs.com/en/business-wire.com/e05b5813b6284a4e3500c1f9144d2dcf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/THtICyvqcBhs1YfiPej9VA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e05b5813b6284a4e3500c1f9144d2dcf","width":960,"height":160},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/YfdOmtQczP5BOz5XwrhOdw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/e05b5813b6284a4e3500c1f9144d2dcf","width":1200,"height":200}},"lazy":false},{"type":"text","content":"MONTPELLIER, France, March 04, 2026--(BUSINESS WIRE)--Regulatory News:","length":70,"tagName":"p"},{"type":"text","content":"Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced its participation to the 2026 Leerink Global Healthcare Conference and Jefferies Biotech on the Beach Summit in Miami, Florida, March 8 – 11, 2026.","length":313,"tagName":"p"},{"type":"text","content":"Meetings with Christophe Douat, Chief Executive Officer, and Dr Grace Kim, Chief Strategy Officer, U.S. Finance, may be arranged via banking conference coordinators or direct contact with Medincell.","length":198,"tagName":"p"},{"type":"text","content":"About Medincell","length":15,"tagName":"p"},{"type":"text","content":"Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.","length":343,"tagName":"p"},{"type":"text","content":"These treatments combine active pharmaceutical ingredients with our proprietary BEPO® / BEPO® Star technologies, which enables controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable deposit.","length":293,"tagName":"p"},{"type":"text","content":"Risperidone LAI was the first treatment based on BEPO® techn...